Ulisse Biomed S.p.A.
UBM.MI · MIL
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.20 | -0.06 | 0.13 |
| FCF Yield | -8.57% | -4.14% | -14.60% | -5.04% |
| EV / EBITDA | -15.70 | -15.64 | -4.48 | -61.36 |
| Quality | ||||
| ROIC | -4.74% | -12.32% | -27.13% | -9.65% |
| Gross Margin | 51.14% | -2,339.68% | -1,115.59% | -234.54% |
| Cash Conversion Ratio | 1.01 | 0.56 | 0.74 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 43.35% | -38.20% | -31.41% | 194.32% |
| Free Cash Flow Growth | -3.98% | -23.83% | 11.26% | -121.76% |
| Safety | ||||
| Net Debt / EBITDA | 1.32 | 1.07 | 3.83 | 14.02 |
| Interest Coverage | -1,736.35 | -24,885.54 | -10,368.72 | -3,584.22 |
| Efficiency | ||||
| Inventory Turnover | 3.11 | 0.81 | 13.01 | 6.17 |
| Cash Conversion Cycle | -645.22 | 12,961.87 | 345.45 | 203.21 |